

SECURITIES AND EXCHANGE COMMISSION

SEC FORM 17-A, *AS AMENDED*

ANNUAL REPORT PURSUANT TO SECTION 17
OF THE SECURITIES REGULATION CODE AND SECTION 141
OF THE CORPORATION CODE OF THE PHILIPPINES

1. For the fiscal year ended ... December 31, 2025
2. SEC Identification Number ... CS201806242 3. BIR Tax Identification No. 009-994-282
4. Exact name of issuer as specified in its charter... Tagum Global Medical Center, Inc.

5. Philippines
Province, Country or other jurisdiction of
incorporation or organization
6. (SEC Use Only)
Industry Classification Code:

7. Room 227 2nd Floor, Gabriel Bldg. Corner Apokon
and National Highway, Tagum City, Davao del Norte
Address of principal office
- 8100
Postal Code

8. 0998-994-8812
Issuer's telephone number, including area code

9. **N/A**
Former name, former address, and former fiscal year, if changed since last report.

10. Securities registered pursuant to Sections 8 and 12 of the SRC, or Sec. 4 and 8 of the RSA

Title of Each Class	Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding (as of December 31, 2025)
Common	217,700 shares
Outstanding debt	P814,800,957

11. Are any or all of these securities listed on a Stock Exchange

Yes [] No [x]

If yes, state the name of such stock exchange and the classes of securities listed therein:

12. Check whether the issuer:

(a) has filed all reports required to be filed by Section 17 of the SRC and SRC Rule 17.1 thereunder or Section 11 of the RSA and RSA Rule 11(a)-1 thereunder, and Sections 26 and 141 of The Corporation Code of the Philippines during the preceding twelve (12) months (or for such shorter period that the registrant was required to file such reports);

Yes

No

(b) has been subject to such filing requirements for the past ninety (90) days.

Yes

No

13. State the aggregate market value of the voting stock held by non-affiliates of the registrant. The aggregate market value shall be computed by reference to the price at which the stock was sold, or the average bid and asked prices of such stock, as of a specified date within sixty (60) days prior to the date of filing. If a determination as to whether a particular person or entity is an affiliate cannot be made without involving unreasonable effort and expense, the aggregate market value of the common stock held by non-affiliates may be calculated on the basis of assumptions reasonable under the circumstances, provided the assumptions are set forth in this Form. (See definition of "affiliate" in "Annex B").

**APPLICABLE ONLY TO ISSUERS INVOLVED IN
INSOLVENCY/SUSPENSION OF PAYMENTS PROCEEDINGS
DURING THE PRECEDING FIVE YEARS:**

14. Check whether the issuer has filed all documents and reports required to be filed by Section 17 of the Code subsequent to the distribution of securities under a plan confirmed by a court or the Commission.

Yes

No

PART I - BUSINESS AND GENERAL INFORMATION

Item 1. Business

TAGUM GLOBAL MEDICAL CENTER, INC. is a stock corporation duly organized under the laws of the Republic of the Philippines on 25 April 2018. It was established to maintain, operate, own, and manage hospitals, medical and related healthcare facilities and businesses such as, but without restriction to clinical laboratories, diagnostic centers, ambulatory clinics, condo hospitals, scientific research and other allied undertakings and services which shall provide medical, surgical, nursing, therapeutic, paramedic, or similar care, provided that purely professional, medical or surgical services shall be performed by duly qualified physicians or surgeons who may or may not be connected with the hospitals and whose services shall be freely and individually contracted by the patients. The Company was issued a Permit to Sell Securities on March 10, 2022 under SEC MSR Order No. 12, Series of 2022.

TAGUM GLOBAL MEDICAL CENTER, INC. aims to be the benchmark of a successful health provider in Davao del Norte by setting up a tertiary health care facility with an organized, systematic, cost-effective, sympathetic and holistic approach to its goal in providing the best quality and justifiable medical services to its clients and stakeholders.

TAGUM GLOBAL MEDICAL CENTER, INC. will further accomplish its mission and purpose through the acquisition of complete and world-class facilities, provide medical specialists who are competent and fully qualified in their line of work, and have equally efficient, well-motivated employees and management staff.

When operational, Tagum Global Medical Center, Inc. will be a 116-bed, Level II, Philhealth accredited hospital in Tagum City in the Province of Davao Del Norte. The medical services will be departmentalized according to specialty, along with the ancillary services such as the laboratory, pharmacy, rehabilitation, radiology and dental services.

The Hospital will serve the patients of Tagum City and other municipalities surrounding the city like Asuncion, Braulio E. Dujali, Carmen, Kapalong and other catchment areas with the main objective of delivering quality health care and services that will be affordable for the Tagumeños.

The registered office of the Company is located at Room 227 2nd Floor, Gabriel Bldg. Corner Apokon and National Highway, Tagum City, Davao del Norte.

The Company has commenced business operation on December 18, 2023 after the construction of the multidisciplinary medical facility (hospital) was completed on December 12, 2023.

The principal suppliers of the Company for its equipment and essential raw materials are the following:

Contractor/ Supplier

Contractor/ Supplier	Description of Contract
Bell-Kenz Pharmacy Inc.	Medicines
Berovan Marketing	Medical Equipment & Instruments
Davao Industrial Compressed Gases Corporation	Medical Supplies
Enhanced Medical & Industrial Enterprises	Electric Dermatome
Fresenius Medical Care Philippines Inc.	Conventional Hemodialysis/Hemodiafiltration

Fujifilm Philippines Inc.	Gastroscope/Colonoscope
Fusion Pharma Distribution Inc.	Medicines
Healthsolutions	Anesthesia Machine
Hospi Care Medical Trading	Medical Supplies
Infratech Medical Devices Inc.	Vein Finder
Jalee Pharmacy	Medicines
Maracare Medical Devices Inc.	ECG Machine
Nipcon Distributors	Medical Supplies
NPK Medical Trading Inc.	Infant Incubator/Cardiac Monitor/Ventilator
Oxford Distibutions Inc.	Medicines
Perpetual Pharmacy	Medicines
Radtelcom Technologies & Industrial Supply	Full HD Laparoscopic Tower
Reign Marketing Inc.	Surgical Operating Microscope/Neuro & Spine Surgical Drill
Respicare Enterprises Inc.	Anesthesia Machine/Cardiac Monitor/Defibrillator/Ventilator/ Stress Test Treadmill
Rozmed Enterprise Inc.	Autoclave/Ventilator
Scientific Biotech Specialties Inc.	Laboratory reagent supplies
Shimadzu Philippine Corp.	Digital Radiographic System/ X-ray Machine
Siemens Healthcare	CT Scan
Touchstar Medical Enterprises Inc.	Laboratory reagent supplies
Zuellig Pharma Corporation	Medicines

The Company is not expected to be dependent upon one or a limited number of suppliers for its hospital equipment and essential raw materials. Issuer has instituted a procurement policy to ensure that it enters into contracts with its suppliers that are most beneficial to the hospital. The Issuer invites at least three (3) bidders for every supply contract that it intends to enter into.

The Company's related parties include its affiliates and shareholders, the Company's key management personnel and others as described below.

A summary of the transactions and account balances with related parties are as follows:

December 31, 2025 (Audited)

Nature of Relationship	Nature of Transaction	Amount (current transaction)	Outstanding balance	Terms	Conditions
Shareholders	Advances from Payments	₱ (26,321,444)	₱ 10,261,874	Non-interest bearing; payable in cash; no scheduled repayment terms	Unsecured
	Loans			Interest bearing; payable in cash; no scheduled	
	Additional loan	5,199,759			Unsecured

				repayment terms
	Payments	-	20,849,759	
	Interest expense	1,929,452		Payable in cash and on demand Unsecured

December 31, 2024 (Audited)

Nature of Relationship	Nature of Transaction	Amount (current transaction)	Outstanding balance	Terms	Conditions
Shareholders	Advances from payment	₱36,583,318	36,583,318	Non-interest bearing; payable in cash; no scheduled repayment terms	Unsecured
	Loans	₱29,650,000		Interest bearing; payable in cash; no scheduled repayment terms	Unsecured
	Additional loan Payments	(76,000,000)	15,650,000	Interest bearing; payable in cash; no scheduled repayment terms	Unsecured
	Interest expense	₱8,632,890		Payable in cash and on demand	Unsecured

December 31, 2023 (Audited)

Nature of Relationship	Nature of Transaction	Amount (current transaction)	Outstanding balance	Terms	Conditions
Shareholders	Advances from Payment	₱(68,332,876)	₱ -	Non-interest bearing; payable in cash; no scheduled repayment terms	Unsecured
	Loans	₱ 34,200,000		Interest bearing; payable in cash; no scheduled repayment terms	Unsecured
	Additional loan Payments	(2,500,000)	₱ 62,000,000	Interest bearing; payable in cash; no scheduled repayment terms	Unsecured
	Interest expense Payments	₱5,036,390 (3,234,801)	₱1,801,589	Payable in cash and on demand	Unsecured

Development Bank of the Philippines

The Company entered into two (2) Term Loan Agreement with the Development Bank of the Philippines (DBP) with a total amount of ₱650M. The amount of loan released as at December 2025, 2024 and 2023 amount to ₱650M.

First Term Loan

The first term loan amounting to ₱500M is payable in twelve (12) years inclusive of a three (3) – year grace period on the principal repayment. The principal is payable in thirty-six (36) quarterly amortizations commencing at the end of the thirteenth (13th) quarter from the date of initial loan release until fully paid. The interest is based on DBP's prevailing rates on the date of loan release 5% - 6% per annum with quarterly repricing and is payable quarterly commencing at the end of the 1st quarter after initial loan release.

Under the terms of the agreement, the proceeds of the loan will be used by the Company to partially finance the construction of a seven (7) storey, 2 Level hospital building and roof deck which is located along National Highway, Barangay Visayan Village, Tagum City, Davao Del Norte. The loan was collateralized by a Real Estate Mortgage (REM) with TCT No. 142-2018008220 registered under the name of Tagum Global Medical Center, Inc. with a carrying amount of ₱947,522,065, ₱943,666,232 and ₱955,267,686 as at December 31, 2025, 2024 and 2023, respectively. (Note 11)

The loan agreement with the banks provides certain restrictions and requirements with respect to among others; a) maintenance of debt to equity ratio of 75:25 and 64:36 debt/equity participation mix for the project, b) not to permit the current ratio to be less than 1:1 at any time, c) not to permit the ratio of its net operating income to total debt service to be less than 1.2:1 at any time, d) incurrence of additional long-term indebtedness or guarantees and e) creation of property encumbrances. The Bank grants a one-year relief from compliance with the financial ratios. Accordingly, the provision in the loan agreement will only be imposed in the year following the Company's commencement of its commercial operations.

Second Term Loan

The second term loan amounting to ₱150M is payable in seven (7) years inclusive of a one (1) – year grace period on the principal repayment. The principal is payable in twenty-four (24) quarterly amortizations commencing at the end of the fifth (5th) quarter from the date of initial loan release until fully paid. The interest is based on DBP's prevailing rates on the date of loan release with quarterly repricing and is payable quarterly commencing at the end of the 1st quarter after initial loan release.

Under the terms of the agreement, the proceeds of the loan will be used by the Company to partially finance the acquisition of various hospital machinery and equipment. The loan was collateralized by a Chattel Mortgage (CHM). The carrying value of hospital equipment used as collateral for this loan amounted to ₱85,226,400, ₱80,622,012, and ₱69,359,207 as at December 31, 2025, 2024, and 2023, respectively. (Note 11)

The loan agreement with the banks provides certain restrictions and requirements with respect to among others; a) maintenance of debt to equity ratio of 75:25 and 64:36 debt/equity participation mix for the project, b) not to permit the current ratio to be less than 1:1 at any time, c) not to permit the ratio of its net operating income to total debt service to be less than 1.2:1 at any time, d) incurrence of additional long-term indebtedness or guarantees and e) creation of property encumbrances. The Bank grants a one-year relief from compliance with the financial ratios. Accordingly, the provision in the loan agreement will only be imposed in the year following the Company's commencement of its commercial operations.

In third quarter of 2023, DBP approved the Company's request for the deferment of the principal repayment of Term Loan 1. The principal repayment which was due in 2023 were added to 2024 quarterly repayment. Consequently, DBP returned the first principal repayment paid by the Company last December 2023.

Tagum Global Medical Center, Inc. has secured the necessary permits and licenses from national and local government entities particularly the Permit to Construct from the Department of Health (DOH) and Environmental Compliance Certificate from DENR.

The License to Operate (LTO) was secured after the full construction of the Hospital and the necessary Occupancy Permit from the Building Official was likewise secured. The DOH conducted an ocular inspection of the facilities of the Hospital, as well as the pre-operation procedures of Tagum Global Medical Center, Inc. to ensure that it is compliant with the standards of the department prior to issuance of the LTO. Other permits may be required later for its operation and shall be complied with by the Hospital.

Required permits such as Building Permit and Business Permit were also secured by the Company from the Office of the City Mayor and from the Business Permit, and Licensing Division respectively.

Total Number of Full Time-Employees (As of December 31, 2025):

	CBA	Non-CBA	Total
Rank and File		267	267
Supervisors		12	12
Managers and Top Management		16	16
Total			295

The major risks involved in the Company's business as well as the measures being undertaken by the Company to manage such risks are as follows:

Major Risks		Measures to be Undertaken
1.	Difficulty to collect from patients	The Issuer can mitigate said risk by setting up a Credit and Collection policies and strategies that will ensure payment of patients and by establishing accreditation standards for Health Maintenance Organizations.
2.	Scarcity of Hospital Staff especially Nurses (once the hospital will start operation)	The Issuer will mitigate such risk through effective advertisement and marketing by the Human Resource Department and will develop programs that will enhance and develop the career path of hospital employees.

Item 2. Properties

The Issuer (select all that apply)

Property	Own	Lease
Land/Building/Real Estate		
Equipment and other long-term assets		
Intangible property such as patents, licenses, copyrights, trademarks, etc.		

Tagum Global Medical Center Inc. is a seven storey (7-storey), 116 bed capacity hospital. The total floor area is around 13,040 square meters constructed in a 5,000 square meters property located at Purok Café, Visayan Village, National Highway Tagum City 8100.

The property is covered by Transfer Certificate of Title Nos. 142-2018008220 registered in the name of Tagum Global Medical Center, Inc.

The Company has an existing credit facility with the Development Bank of the Philippines in the principal amount of P650 Million. The loan consists of two packages, i.e., Term Loan 1 for the hospital construction and Term Loan 2 for hospital equipment. The loan is available in several draw downs where the bank will conduct an inspection to see the progress of the construction. The first tranche of P100 Million and the second tranche of P75 Million are payable until December 4, 2031 with a current interest rate of 5%-6% per annum subject to quarterly repricing. The loan is secured by a mortgage on the Issuer's property where the hospital is situated with an area of 5,000 square meters together with all the permanent improvements and personal properties built and installed thereon.

The corporation has also acquired the adjacent lot of 14,000 square meters payable in 7 installments at P13,000,000.00 per installment with a total purchase price of P91,000,000.00. As of December 31, 2021, the total amount has been fully paid. The Deed of Absolute Sale and transfer of the title will be made upon full payment of the purchase price or consideration. As of reporting date, the title has not yet been transferred to the Company. The property will be used for future expansion of the hospital.

As of December 31, 2025, the percentage of construction of the building is at 100%. The hospital facility will be a 7-storey building with roof deck, as follows:

<i>Ground Floor</i>	2,180.00	sq.m
<i>Second Floor</i>	2,175.00	sq.m
<i>Third Floor</i>	2,175.00	sq.m
<i>Fourth Floor</i>	1,516.00	sq.m
<i>Fifth Floor</i>	1,516.00	sq.m
<i>Sixth Floor</i>	1,516.00	sq.m
<i>Seventh Floor</i>	1,516.00	sq.m
<i>Roof Deck Floor Area</i>	446.00	sq.m

Item 3. Legal Proceedings

The Company is not involved in any legal proceeding.

PART II – SECURITIES OF THE REGISTRANT

A. Market Price of and Dividends on Registrant's Common Equity and Related Stockholder Matters

(1) Market Information

The Company's common equity are sold through its own internal staff. The shares are sold in tranches for easier administration and on a first-come, first-served basis, subject to pre-qualification procedures. The high and low sales prices by quarter for the last two (2) years are as follows:

	1st Quarter		2nd Quarter		3rd Quarter		4th Quarter		1st Quarter
<i>Market Price</i>	2024	2025	2024	2025	2024	2025	2024	2025	2026

High	300,000	300,000	300,000	300,000	300,000	300,000	300,000	300,000	300,000
Low	300,000	300,000	300,000	300,000	300,000	300,000	300,000	300,000	300,000

**The Company's Permit to Sell Securities was issued on March 10, 2022 under SEC MSRD Order No. 12, Series of 2022.*

The price as of April 17, 2024, (latest practicable trading date) is P 300,000.00 per block (10 shares).

(2) Holders

There are approximately 1430 holders of common shares of the Company as of 31 December 2025.

Top 20 Stockholders (As of 31 December 2025)

Name of Stockholders	Nationality	No. of Shares	Percentage of Ownership
Carlos, Fernando P.	Filipino	F 10	1.63%
		C 3,390	
Enriquez, Amado Manuel, Jr. C.	Filipino	F 90	14.68%
		C 30,510	
Enriquez, Michael Edward R.	Filipino	F 30	4.89%
		C 10,170	
Enriquez, Miguel Antonio R.	Filipino	F 30	4.89%
		C 10,170	
Viernes, La Rhaine G.	Filipino	F 10	1.63%
		C 3,390	
Dalisay, Mae T.	Filipino	F 20	3.333%
		C 6,780	
Carlos, Fernando P.	Filipino	F 10	1.63%
		C 3,390	
Cerna-Lopez, Geanie	Filipino	F 10	1.63%
		C 3,390	
Cu, Dorothy Mildred S.	Filipino	F 10	1.63%
		C 3,390	
Del Fierro, Jose Emmanuel S.	Filipino	F 10	1.63%
		C 3,390	
Demegillo, Kenny Jun N.	Filipino	F 10	1.63%
		C 3,390	
Guillano, Franklin B.	Filipino	F 10	1.63%
		C 3,390	
Jaya, Maria Pilipinas D.	Filipino	F 10	1.63%
		C 3,390	
Juarez, Mariebeth P.	Filipino	F 10	1.63%
		C 3,390	
Nuevas, Nimfa L.	Filipino	F 10	1.63%
		C 3,390	
Orillaza, Generoso M.	Filipino	F 10	1.63%
		C 3,390	
Perdido, Evelyn Ross H.	Filipino	F 10	1.63%
		C 3,390	
Samoro, Fredilyn G.	Filipino	F 10	1.63%

		C	3,390	
Samoy, Marietta T.	Filipino	F	10	1.63%
		C	3,390	
Valencia, Orlando A.	Filipino	F	10	1.63%
		C	3,390	
Others		F	270	46.18%
		C	95,990	
Total		F	600	100%
		C	207,860	

(3) Dividends

Dividend Information on the Two Most Recent Fiscal Years

No dividends were declared by the Company since its incorporation in 2018.

As stated in the Company's By-Laws, dividends shall be declared and paid out of the unrestricted retained earnings which shall be payable in cash, property, or stock to all stockholders on the basis of outstanding stock held by them as often and as such times as decided on the Board of Directors.

Based on the Issuer's loan agreement with the DBP, dividend declarations shall be subject to the approval of the Bank.

There is no recent sale of unregistered or exempt securities.

PART III. FINANCIAL INFORMATION

A. Management's Discussion and Analysis or Plan of Operation

Management's Discussion and Analysis

The following table shows the consolidated financial highlights of the Company for the years then ended December 31, 2025, 2024 and 2023:

	<i>As of December 31</i>		
	<i>2025</i>	<i>2024</i>	<i>2023</i>
Income Statement Data			
Revenue	P355,930,742	P183,033,578	P735,623
Cost of sales and services	(224,731,396)	(144,369,785)	(2,776,774)
Other income	5,003,530	3,600,561	412,894
Operating expenses	(60,583,954)	(38,503,333)	(26,155,555)
Finance costs	(57,420,080)	(56,503,113)	(3,225,146)
Income tax benefit (expense)	(5,136,602)	11,024,067	7,685,476
Net Income (Loss)	P13,062,240	(P41,718,025)	(P23,353,482)

As disclosed in the Note 1 in the financial statements, the Company was incorporated on April 25, 2018 and has launched the full opening and full commercial operations of its hospital building and facilities in December 18, 2023.

Revenue

Revenue generated for the year ended 2025 amounted to ₱356M. The Hospital is in its second year of full operation and gained more patients as compared to 2024 which is just the start of full operation.

Cost of Sales and Services

Cost of sales and services for the year ended 2025 amounted to ₱245M. As the Company gained more patient and started creating a name in Tagum on its second year of full operation, the increase in revenue would also means increase in cost of sales and services.

Other Income

Other income increased by 39%. This was mainly due hospital's second year of full operation which have gained additional patients, increasing the income from canteen and other miscellaneous income.

Operating Expenses

Operating expenses during December 31, 2025 are higher compared to December 31, 2024 expenses by 57%. This is primarily due to additional administrative expenses of the Company such as salaries and wages, taxes and licenses, transportation expenses, communication expenses, professional fee, repairs and maintenance and bank charges.

Finance Costs

Finance costs increased by 1.62%. This was due to deferment of payment of principal.

Income tax benefit (expense)

The Company incurred income tax expense for the year 2025 due to positive result of operation as compared to loss in 2024.

Net income (loss) for the year

The positive result of operation in 2025 as compared to loss in 2024 is attributable to the Company's effort to make TGMCI known in Tagum area, gaining more patients on its second year of operation.

Financial Condition

Total assets increased from ₱1,171.9M to ₱1,239.4M, a 5.76% increase from December 31, 2024. The increase was caused by the increase in cash, inventories, prepayments and other current assets, property and equipment, intangible asset and financial asset at FVOCI. This was negated by the decrease in trade and other receivables, advances to contractors and suppliers and deferred tax asset.

Cash increased by ₱49.1M or 621% primarily due to proceeds from issuance of shares and cash generated from operation. This is negated by acquisition of property and equipment and principal and interest payments on loans and payment of advances.

Receivables decreased by ₱7.50M primarily due to collections of receivables.

Inventories increased by ₱12.27M mainly due to increase in laboratory supplies, hospital supplies, office supplies, linen supplies and linen supplies.

Increase in prepayments and other current assets by ₱9.40M was primarily due to additional VAT input and prepaid income tax.

Advances to contractors and suppliers decreased by ₱1.62M primarily due to reclassification of the down payments related to the medical equipment, office equipment and furniture and other hospital equipment.

Property and equipment increased by ₱10.83M primarily due to the additional acquisition of medical equipment, office equipment/furniture and fixtures, transportation equipment and building and building improvements. This is negated by depreciation expense for the period.

Intangible assets increased by ₱.070M due to additional cost of the hospital information system and other system needed for the hospital operation, negated by the amortization for the period.

Financial assets at FVOCI increase by ₱450. This was due to the rebates earned for the year 2025.

There is no movement in the amount of refundable deposit from 2024 to 2025.

Deferred tax asset decreased by ₱5.14M due to the application of NOLCO, negated by the DTA arising from credit losses in 2025.

Total liabilities increased by ₱10.43M. The increase was primarily due to increase in trade and other payables and other current liabilities in relation to the growing operation of the hospital and the reclassification of the presentation of deposit for future stock subscription from equity to liability. This is negated by the decrease in advances and loans payable.

Trade and other payables increased by ₱48.20M. This increase was primarily due to increase in trade payable in relation to acquisition of property and equipment and additional liabilities incurred in relation to the Company's growing operation.

Advances from shareholders decreased by ₱26.32M primarily due to payment of advances from shareholders.

Loans payable represents interest-bearing loan from Banks and shareholders in support of the construction of the Company's hospital building and hospital equipment. The decrease was mainly due to the payment of loans amounting to ₱24.15M.

The ₱57.04M increase in total equity is primarily due to the additional share premium and issuance of share capital for the year and the positive result of operation for the year 2025 causing a decrease in the accumulated deficit. This was negated by the reclassification of the presentation of deposit for future stock subscription from equity to liability.

Key Performance Indicators

	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
1. Liquidity			
a. Quick ratio - capacity to cover its short-term obligations using only its most liquid assets. [(cash + receivables) / current liabilities]	0.535:1	0.342:1	0.284:1
b. Current ratio - capacity to meet current obligations out of its	0.586:1	0.358:1	0.286:1

liquid assets. (current assets / current liabilities)			
2. Solvency a. Debt to equity ratio - indicator of which group has the greater representation in the assets of the Company. (total liabilities / equity)	1.919:1	2.189:1	2.754:1
3. Profitability a. Net profit margin - ability to generate surplus for stockholder (net income / sales) - Remarks: The ratio is not applicable in 2022 and 2021 since the Company is still at pre-operating stage. b. Return on equity - ability to generate returns on investment of stockholders. (net income / equity)	0.037:1	(0.228:1)	(31.747:1)
4. Leverage b. Debt to total asset ratio - the proportion of total assets financed by creditors. (total liabilities / total assets) c. Asset to equity ratio - indicator of the overall financial stability of the Company. (total assets / equity)	0.657:1	0.686:1	0.734:1
2. Interest Rate Coverage Ratio a. Interest rate coverage ratio - measure of the company's ability to meet its interest payments (earnings before interest and taxes / interest expense)	2.919:1	3.189:1	3.754:1
2. Interest Rate Coverage Ratio a. Interest rate coverage ratio - measure of the company's ability to meet its interest payments (earnings before interest and taxes / interest expense)	1.317:1	0.067:1	(8.535:1)

DECEMBER 31, 2025 COMPARED TO DECEMBER 31, 2024

	For The Year Ended		Horizontal Analysis		Vertical Analysis	
	31-Dec-2025	31-Dec-2024	Inc (Dec)	%age	31-Dec-2025	31-Dec-2024
Revenues	₱ 355,930,742	₱ 183,033,578	₱ 172,897,164	94%	100%	100%
Cost of sales and services	(224,731,396)	(144,369,785)	(80,361,611)	56%	-63%	-377%
Other income	5,003,530	3,600,561	1,402,969	39%	1%	56%
Operating expenses	(60,583,954)	(38,503,333)	(22,080,621)	57%	-17%	-3556%
Finance costs	(57,420,080)	(56,503,113)	(916,967)	2%	-16%	-443%
Income tax (expense) benefit	(5,136,602)	11,024,067	(16,160,669)	-147%	-1%	1045%
Net loss	₱ 13,062,240	₱ (41,718,025)	₱ 54,780,265	-131%	4%	-23%

Changes in Operating Results

Revenue generated for the year ended 2025 amounted to ₱356M. The Hospital is in its second year of full operation and gained more patients as compared to 2024 which is just the start of full operation.

Cost of sales and services for the year ended 2025 amounted to ₱245M. As the Company gained more patient and started creating a name in Tagum on its second year of full operation, the increase in revenue would also means increase in cost of sales and services.

Other income increased by 39%. This was mainly due hospital's second year of full operation, which have gained additional patients, increasing the income from canteen and other miscellaneous income.

Operating expenses during December 31, 2025 are higher compared to December 31, 2024 expenses by 57%. This is primarily due to additional administrative expenses of the Company such as salaries and wages, taxes and licenses, transportation expenses, communication expenses, professional fee, repairs and maintenance and bank charges.

Finance costs increased by 1.62%. This was due to deferment of payment of principal.

The Company incurred income tax expense for the year 2025 due to positive result of operation as compared to loss in 2024.

The positive result of operation in 2025 as compared to loss in 2024 is attributable to the Company's effort to make TGMCI known in Tagum area, gaining more patients on its second year of operation.

	31-Dec-2025	31-Dec-2024	Horizontal Analysis		Vertical Analysis		
			Inc(Dec)	%age	31-Dec-2025	31-Dec-2024	
ASSETS							
Current Assets							
Cash	₱ 57,056,864	₱ 7,916,354	₱ 49,140,510	621%	5%	1%	
Trade and other receivables	54,908,580	62,404,351	(7,495,771)	-12%	4%	5%	
Inventories	31,969,645	19,701,018	12,268,627	62%	3%	2%	
Prepayments and other current assets	13,682,048	4,274,019	9,408,029	220%	1%	0%	
Total Current Assets	157,617,137	94,295,742	63,321,395	67%	13%	8%	
Non-current Assets							
Advances to contractors and suppliers	13,585,151	15,200,701	(1,615,550)	-11%	1%	1%	
Property and equipment - net	1,049,724,651	1,038,894,124	10,830,527	1%	85%	89%	
Intangible asset, net	1,086,667	1,016,667	70,000	0%	0%	0%	
Financial Asset at FVOCI	4,950	4,500	450	10%	0%	0%	
Refundable deposit	2,653,611	2,653,611	-	0%	0%	0%	
Deferred tax asset	14,682,110	19,818,712	(5,136,602)	-26%	1%	2%	
Total Non-Current Assets	1,081,737,140	1,077,588,315	4,148,825	0%	87%	92%	
Total Assets	₱ 1,239,354,277	₱ 1,171,884,057	₱ 67,470,220	6%	100%	100%	
LIABILITIES AND EQUITY							
Current Liabilities							
Payables	₱ 162,837,562	₱ 114,641,025	₱ 48,196,537	42%	13%	10%	
Advances from shareholders	10,261,874	36,583,318	(26,321,444)	0%	1%	3%	
Loans payable - current	81,481,338	110,650,000	(29,168,662)	-26%	7%	9%	
Deposit for future stock subscription	10,000,000	-	10,000,000	100%	1%	0%	
Other current liabilities	4,401,762	1,691,884	2,709,878	160%	0%	0%	
Total Current Liabilities	268,982,536	263,566,227	5,416,309	2%	22%	22%	
Non-Current Liabilities							
Loans payable - non current	545,818,421	540,800,000	5,018,421	1%	44%	46%	
Total Liabilities	814,800,957	804,366,227	10,434,730	1%	66%	69%	
Equity							
Share capital	218,300,000	216,910,000	1,390,000	1%	18%	19%	
Share premium	273,200,000	220,616,750	52,583,250	24%	22%	19%	
Deposit for future stock subscription	-	10,000,000	(10,000,000)	-100%	0%	1%	
Accumulated deficit	(66,946,680)	(80,008,920)	13,062,240	-16%	-5%	-7%	
Equity, Net	424,553,320	367,517,830	57,035,490	16%	100%	100%	
Total Liabilities and Equity	₱ 1,239,354,277	₱ 1,171,884,057	₱ 67,470,220	6%	100%	100%	

Financial Condition

Total assets increased from ₱1,171.9M to ₱1,239.4M, a 5.76% increase from December 31, 2024. The increase was caused by the increase in cash, inventories, prepayments and other current assets, property and equipment, intangible asset and financial asset at FVOCI. This was negated by the

decrease in trade and other receivables, advances to contractors and suppliers and deferred tax asset.

Cash increased by ₱49.1M or 621% primarily due to proceeds from issuance of shares and cash generated from operation. This is negated by acquisition of property and equipment and principal and interest payments on loans and payment of advances.

Receivables decreased by ₱7.50M primarily due to collections of receivables.

Inventories increased by ₱12.27M mainly due to increase in laboratory supplies, hospital supplies, office supplies, linen supplies and linen supplies.

Increase in prepayments and other current assets by ₱9.40M was primarily due to additional VAT input and prepaid income tax.

Advances to contractors and suppliers decreased by ₱1.62M primarily due to reclassification of the down payments related to the medical equipment, office equipment and furniture and other hospital equipment.

Property and equipment increased by ₱10.83M primarily due to the additional acquisition of medical equipment, office equipment/furniture and fixtures, transportation equipment and building and building improvements. This is negated by depreciation expense for the period.

Intangible assets increased by ₱.070M due to additional cost of the hospital information system and other system needed for the hospital operation, negated by the amortization for the period.

Financial assets at FVOCI increase by ₱450. This was due to the rebates earned for the year 2025.

There is no movement in the amount of refundable deposit from 2024 to 2025.

Deferred tax asset decreased by ₱5.14M due to the application of NOLCO, negated by the DTA arising from credit losses in 2025.

Total liabilities increased by ₱10.43M. The increase was primarily due to increase in trade and other payables and other current liabilities in relation to the growing operation of the hospital and the reclassification of the presentation of deposit for future stock subscription from equity to liability. This is negated by the decrease in advances and loans payable.

Trade and other payables increased by ₱48.20M. This increase was primarily due to increase in trade payable in relation to acquisition of property and equipment and additional liabilities incurred in relation to the Company's growing operation.

Advances from shareholders decreased by ₱26.32M primarily due to payment of advances from shareholders.

Loans payable represents interest-bearing loan from Banks and shareholders in support of the construction of the Company's hospital building and hospital equipment. The decrease was mainly due to the payment of loans amounting to ₱24.15M.

The ₱57.04M increase in total equity is primarily due to the additional share premium and issuance of share capital for the year and the positive result of operation for the year 2025 causing a decrease in the accumulated deficit. This was negated by the reclassification of the presentation of deposit for future stock subscription from equity to liability.

DECEMBER 31, 2024 COMPARED TO DECEMBER 31, 2023

	For The Year Ended		Horizontal Analysis		Vertical Analysis	
	31-Dec-2024	31-Dec-2023	Inc (Dec)	%age	31-Dec-2024	31-Dec-2023
Revenues	₱ 183,033,578	₱ 735,623	₱ 182,297,955	24781%	100%	100%
Cost of sales and services	(144,369,785)	(2,776,774)	(141,593,011)	5099%	-79%	-377%
Other income	3,600,561	412,894	3,187,667	772%	2%	56%
Operating expenses	(38,503,333)	(26,155,555)	(12,347,778)	47%	-21%	-3556%
Finance costs	(56,503,113)	(3,255,146)	(53,247,967)	1636%	-31%	-443%
Income tax benefit	11,024,067	7,685,476	3,338,591	43%	6%	1045%
Net loss	₱ (41,718,025)	₱ (23,353,482)	₱ (18,364,543)	79%	-23%	-3175%

Changes in Operating Results

Revenue generated for the year ended 2024 amounted to ₱183M. This was due to start of the Company's full operation of the hospital in 2024.

Cost of sales and services for the year ended 2024 amounted to ₱144M. This was directly associated with the start of the Company's full operation in 2024. The major component of the cost of sales and services are employee's compensation and benefits, supplies, depreciation, outside services, utilities, dietary expenses and professional fees.

Other income increased by 772%. This is primarily due to increase in interest income, income from cafeteria and miscellaneous income in relation to the operation of the hospital.

Operating expenses during December 31, 2024 are higher compared to December 31, 2023 expenses by %. This is primarily due to increase in taxes and licenses, transportation, professional fee, salaries and wages insurance, recruitment expenses, outside services, office supplies and all expenses in relation to the full operation of the hospital.

Income tax benefit increased by 43% was primarily due to higher expenses resulting to higher taxable loss for the year 2024.

Loss for the year ended December 31, 2024 is higher than in 2023 by 79% primarily due to the significant increase of expenses as the Company started the full operation of the hospital 2024.

	31-Dec-2024		31-Dec-2023		Horizontal Analysis		Vertical Analysis		
					Inc(Dec)	%age	31-Dec-2024	31-Dec-2023	
ASSETS									
Current Assets									
Cash	₱	7,916,354	₱	64,287,204	₱	(56,370,850)	-88%	1%	6%
Receivables		62,404,351		119,015		62,285,336	52334%	5%	0%
Inventories		19,701,018		1,626,820		18,074,198	1111%	2%	0%
Prepayments and other current assets		4,274,019		335,325		3,938,694	1175%	0%	0%
Total Current Assets		94,295,742		66,368,364		27,927,378	42%	8%	6%
Non-current Assets									
Advances to contractors and suppliers		15,200,701		18,031,152		(2,830,451)	-16%	1%	2%
Property and equipment - net		1,038,894,124		1,038,855,991		38,133	0%	89%	92%
Intangible asset, net		1,016,667		-		1,016,667	0%	0%	0%
Financial Asset at FVOCI		4,500		3,850		650	17%	0%	0%
Refundable deposit		2,653,611		2,443,611		210,000	9%	0%	0%
Deferred tax asset		19,818,712		8,794,645		11,024,067	125%	2%	1%
Total Non-Current Assets		1,077,588,315		1,068,129,249		9,459,066	1%	92%	94%
Total Assets	₱	1,171,884,057	₱	1,134,497,613	₱	37,386,444	3%	100%	100%
LIABILITIES AND EQUITY									
Current Liabilities									
Payables	₱	114,641,025	₱	119,778,297	₱	(5,137,272)	-4%	10%	11%
Advances from shareholders		36,583,318		-		36,583,318	0%	3%	0%
Loans payable - current		110,650,000		112,000,000		(1,350,000)	-1%	9%	10%
Other current liabilities		1,691,884		541,631		1,150,253	212%	0%	0%
Total Current Liabilities		263,566,227		232,319,928		31,246,299	13%	22%	20%
Non-Current Liabilities									
Loans payable - non current		540,800,000		600,000,000		(59,200,000)	-10%	46%	53%
Total Liabilities		804,366,227		832,319,928		(27,953,701)	-3%	69%	73%
Equity									
Share capital		216,910,000		142,120,000		74,790,000	53%	19%	13%
Share premium		220,616,750		188,348,580		32,268,170	17%	19%	17%
Deposit for future stock subscription		10,000,000		10,000,000		-	0%	1%	1%
Accumulated deficit		(80,008,920)		(38,290,895)		(41,718,025)	109%	-7%	-3%
Equity, Net		367,517,830		302,177,685		65,340,145	22%	100%	100%
Total Liabilities and Equity	₱	1,171,884,057	₱	1,134,497,613	₱	37,386,444	3%	100%	100%

Financial Condition

Total assets increased from ₱1,134.5M to ₱1,171.9M, a 3% increase from December 31, 2023. The increase was due to the significant increase in receivables, inventories, prepayments and other current assets property and equipment, financial asset at FVOCI, refundable deposits and deferred tax asset, negated by the significant decrease in cash and advances to contractors and suppliers.

Cash decreased by ₱56.4M or 88% primarily due to additional acquisition of equipment and furniture and fixtures and operational expenses. This was partly negated by the proceeds from issuance of shares and receipts from commencement of full operation of the hospital in 2024.

Receivables increased by ₱62.28M primarily due to the commencement of full operation of the hospital in 2024.

Inventories increased by ₱18.07M due to additional purchases of hospital, dietary and office supplies due to full operation of the hospital in 2024.

Increase in prepayments and other current assets by ₱3.93M was primarily due to additional VAT input and prepaid income tax and this was negated by prepaid insurance and prepaid withholding tax on compensation.

Advances to contractors and suppliers decreased by ₱2.83M was primarily due to reclassification of the down payments related to the medical equipment, office equipment and furniture and other hospital equipment.

Property and equipment increased by ₱38K primarily due to the additional acquisition of medical equipment, office equipment/furniture and fixtures, transportation equipment and other hospital equipment and partly negated by depreciation expense for the period.

Intangible assets increased by ₱1.01M due to use of hospital information system in relation to the full operation of the hospital in 2024. This is net of amortization for the year.

Financial asset at FVOCI increase by ₱650. This was due to the rebates earned for the year 2024.

Refundable deposit increased by ₱210K primarily due to additional deposits in deposits paid for oxygen tanks.

Deferred tax asset increased by ₱11.02M due to the tax effect of additional losses incurred by the Company for the year 2024.

Total liabilities increased by ₱3.29M. The increase was primarily due to the additional loan availed by the company during the year 2024, advances from shareholder and other current liabilities from government agencies for the period.

Payables decreased by ₱5.14M. This decrease was mainly due to payments of retention payable in relation with the Company's construction of hospital building which was completed in the fourth quarter of 2023. This was negated by additional accounts, accrued expenses of unpaid professional fees and interests on loans.

Advances from shareholders increased by ₱36.59M primarily due to additional advances from shareholders for operation expenses.

Loans payable represents interest-bearing loan from Banks and shareholders in support of the construction of the Company's hospital building and hospital equipment. The increase was mainly due to the additional loan release from shareholders amounting to ₱29.65M which was negated by the payment of loans amounting to ₱90.20M, resulting to a net decrease in loans payable of ₱60.55M in 2024.

The ₱65.3M increase in the total equity is primarily due to the additional share premium and issuance of share capital for the year. This was negated by the negative result of operation from 2024.

DECEMBER 31, 2023 COMPARED TO DECEMBER 31, 2022

Changes in Operating Results

Revenue generated for the year ended 2023 amounted to ₱.735M. This was due to start of the Company's full operation of the hospital in December 2023

Cost of sales and services for the year ended 2023 amounted to ₱2.78M. This was directly associated with the start of the Company's full operation in December 2023. The major component of the cost of sales and services, employee's compensation and benefits, supplies, depreciation, outside services, utilities, dietary expenses and professional fees.

Other income increased by 4,232%. This is primarily due to increase in interest income, income from cafeteria and miscellaneous income in relation to the operation of the hospital.

Operating expenses during December 31, 2023 are higher compared to December 31, 2022 expenses by 971%. This is primarily due to increase in taxes and licenses, professional fee, salaries and wages insurance, recruitment expenses, outside services, office supplies and all expenses in relation to the full operation of the hospital in December 2023.

Income tax benefit increased by 1,247% was primarily due to higher expenses resulting to higher taxable loss for the year 2023.

Loss for the year ended December 31, 2023 is higher than in 2022 by 1,155% primarily due to the significant increase of expenses as the Company started the full operation of the hospital in December 2023.

Financial Condition

Total assets increased from ₱775.5M to ₱1,134.5M, a 46% increase from December 31, 2022. The increase was due to the significant increase in cash, receivables, inventories, prepayments and other current assets property and equipment, financial asset at FVOCI, refundable deposits and deferred tax asset, negated by the significant decrease in advances to contractors and suppliers.

Cash increased by ₱55.9M or 670% primarily due to additional loan release from DBP, proceeds from issuance of shares and receipts from commencement of full operation of the hospital in December 2023. This was partly negated by the expenditures on the construction of the hospital building, acquisition of equipment and furniture and fixtures and the operating expenses for the period.

Receivables increased by ₱119,015 primarily due to employee's additional reimbursement of sickness benefit and advances for training.

The increase in inventories pertains mainly to purchases of medicine and medical supplies.

Increase in prepayments and other current assets by ₱.123M was primarily due to the decreased in prepaid insurance and prepaid withholding tax on compensation, though there was an additional VAT input.

Advances to contractors and suppliers decreased by ₱5.2M was primarily due to reclassification of the down payments related to the medical equipment, office equipment and furniture and other hospital equipment.

Property and equipment increased by ₱296.3M primarily due to the additional capital expenditures on the construction of the hospital building and acquisition of medical equipment, office

equipment/furniture and fixtures, transportation equipment and other hospital equipment and partly negated by depreciation expense for the period. In December 2023, the Company launched the full opening and full commercial operations of its hospital building and facilities, hence Construction-in-progress was reclassified to Hospital Building Account by ₱816.74M.

Financial asset at FVOCI increase by ₱600. This was due to the rebates earned for the year 2023.

Refundable deposit increased by ₱2.44M primarily due to additional deposits in utility and deposits paid for oxygen tanks.

Deferred tax asset increased by ₱7.69M due to the tax effect of losses incurred by the Company for the year 2023.

Total liabilities increased by ₱240.5M. The increase was primarily due to the additional loan availed by the company during the year 2023, payables in relations to the construction of the hospital building and other current liabilities from government agencies in the commencement of hospital full operation in December 2023 and these were negated by additional payment to advances from shareholders.

Payables increased by ₱76.99M. This increase was mainly due to the additional accounts and retention payable in relation with the Company's construction of hospital building which was completed in the fourth quarter of 2023. This was negated by accrued expenses of unpaid professional fees and interests on loans.

Advances from shareholders was fully paid in 2023.

Loans payable represents interest-bearing loan from Banks and shareholders in support of the construction of the Company's hospital building and hospital equipment. The increase was mainly due to the additional loan release from Development Bank of the Philippines and shareholders amounting to ₱234.2M which was negated by the payment of loans payable to related party amounting to ₱2.5M, resulting to a net increase in loans payable of ₱231.7M in 2023.

The ₱118.44M increase in the total equity is primarily due to the additional share premium and issuance of share capital for the year. This was negated by the negative result of operation from December 2023.

Material Changes in Financial Condition

From January 1, 2025 to December 31, 2025	From January 1, 2024 to December 31, 2024	From January 1, 2023 to December 31, 2023
<p>a. Cash increased by ₱49.14M This is primarily due to proceeds from issuance of shares and cash generated from operation. This is negated by acquisition of property and equipment and principal and interest payments on loans and payment of advances.</p>	<p>a. Cash decreased by ₱56.4M This is primarily due to additional acquisition of equipment and furniture and fixtures and operational expenses. This was partly negated by the proceeds from issuance of shares and receipts from commencement of full operation of the hospital in 2024.</p>	<p>a. Cash increased by ₱55.9M This is primarily due to additional loan release from DBP, proceeds from issuance of shares and receipts from commencement of full operation of the hospital in December 2023. This was partly negated by the expenditures on the construction of the hospital building, acquisition of equipment and furniture and fixtures and the operating expenses for the period.</p>
<p>b. Receivables decreased by ₱7.50M Primarily due to collection of receivables.</p>	<p>b. Receivables increased by ₱62.28M Due to employee's additional reimbursement of sickness benefit and receipts from commencement of full operation of the hospital in 2024.</p>	<p>b. Receivables increased by ₱.119M Due to employee's additional reimbursement of sickness benefit and advances for training.</p>
<p>c. Inventories increased by ₱12.27M Mainly due to increase in laboratory supplies, hospital supplies, office supplies, linen supplies and linen supplies.</p>	<p>c. Inventories increased by ₱18.07M Due to additional purchases of hospital, dietary and office supplies due to full operation of the hospital in 2024.</p>	<p>c. Inventories increase by ₱1.62M Due to purchases of medicine and medical supplies in the commencement of operation in December 2023.</p>
<p>d. Prepayments and other current assets increased by ₱9.40M Primarily due to additional VAT input and prepaid income tax.</p>	<p>d. Prepayments and other current assets increased by ₱3.93M was primarily due to additional VAT input and prepaid income tax and this was negated by prepaid insurance and prepaid withholding tax on compensation.</p>	<p>d. Prepayments and other current assets increased by ₱.123M primarily due to additional VAT input and this was negated by prepaid insurance and prepaid withholding tax on compensation.</p>
<p>e. Advances to contractors and suppliers decreased by ₱1.62M Primarily due to reclassification of the down payments related to the medical equipment, office equipment and furniture and other hospital equipment.</p>	<p>e. Advances to contractors and suppliers was decreased by ₱2.83M Due reclassification of the down payments related to the medical equipment, office equipment and furniture and other hospital equipment.</p>	<p>e. Advances to contractors and suppliers was decreased by ₱5.2M Due to reclassification of the down payments related to the medical equipment, office equipment and furniture and other hospital equipment.</p>
<p>f. Property and equipment increased by ₱10.83M Primarily due to the additional acquisition of medical equipment, office equipment/furniture and fixtures, transportation equipment and building and building improvements. This is negated by depreciation expense for the period.</p>	<p>f. Property and equipment increased by ₱38K primarily due to the additional acquisition of medical equipment, office equipment/furniture and fixtures, transportation equipment and other hospital equipment and partly negated by depreciation expense for the period.</p>	<p>f. Property and equipment increased by ₱296.3M primarily due to the additional capital expenditures on the construction of the hospital building and acquisition of medical equipment, office equipment/furniture and fixtures, transportation equipment and other hospital equipment and partly negated by depreciation expense for the period. In December 2023, the Company launched the full opening and full commercial operations of its hospital building and facilities, hence Construction-in-progress was reclassified to Hospital Building Account by ₱816.74M.</p>

<p>g. Intangible assets increased by ₱0.07M Due to additional cost of the hospital information system and other system needed for the hospital operation, negated by the amortization for the period.</p>	<p>g. Intangible assets increased by ₱1.01M Due to use of hospital information system in relation to full operation of the hospital.</p>	
<p>h. Financial Asset at FVOCI increased by ₱450 Due to rebates earned in 2025.</p>	<p>h. Financial Asset at FVOCI increased by ₱650 Due to rebates earned in 2024.</p>	<p>h. Financial Asset at FVOCI increased by ₱600 Due to rebates earned in 2023.</p>
<p>i. No Movement on Refundable Deposit</p>	<p>i. Refundable deposit increased by ₱210K Due to additional deposits in deposits paid for oxygen tanks.</p>	<p>i. Refundable deposits increased by ₱2.44M Due to additional deposits to utility and deposits paid for the oxygen tanks.</p>
<p>j. Deferred tax asset decreased by ₱5.14M Due to the application of NOLCO, negated by the DTA arising from credit losses in 2025.</p>	<p>j. Deferred tax asset increased by ₱11.02M due to the tax effect of losses incurred by the Company for the year 2024.</p>	<p>j. Deferred tax asset increased by ₱7.69M due to the tax effect of losses incurred by the Company for the year 2023.</p>
<p>k. Trade and other payables increased by ₱48.20M This increase was primarily due to increase in trade payable in relation to acquisition of property and equipment and additional liabilities incurred in relation to the Company's growing operation.</p>	<p>k. Trade and other payables decreased by ₱5.14M This decrease was mainly due to payments of retention payable in relation with the Company's construction of hospital building which was completed in the fourth quarter of 2023. This was negated by additional accounts, accrued expenses of unpaid professional fees and interests on loans.</p>	<p>k. Payables increased by ₱76.99M This increase was mainly due to the additional accounts and retention payable in relation with the Company's construction of hospital building which was completed in the fourth quarter of 2023. This was negated by accrued expenses of unpaid professional fees and interests on loans.</p>
<p>l. Loans payable decreased by ₱24.15M The decrease was mainly due to payment of loans.</p>	<p>l. Loans payable net increased by ₱60.55M The increase was mainly due to the additional loan release from shareholders amounting to ₱29.65M which was negated by the payment of loans payable to bank and related party amounting to ₱90.20M</p>	<p>l. Loans payable net increased by ₱231.7M The increase was mainly due to the additional loan release from Development Bank of the Philippines and shareholders amounting to ₱234.2M which was negated by the payment of loans payable to related party amounting to ₱2.5M</p>
<p>m. Advances from shareholders decreased by ₱26.32M Primarily due to payment of advances.</p>	<p>m. Advances from shareholders increased by ₱36.59M Primarily due to additional advances from shareholders for operation expenses.</p>	<p>m. Advances from shareholders decreased by ₱68.3M This was fully paid in 2023.</p>
<p>n. Equity increased by ₱57.04M Primarily due to the additional share premium and issuance of share capital for the year and the positive result of operation for the year 2025 causing a decrease in the accumulated deficit. This was negated by the reclassification of the presentation of deposit for future stock subscription from equity to liability.</p>	<p>n. Equity increased by ₱65.3M primarily due to the additional share premium and issuance of share capital for the year. This was negated by the negative result of operation from 2024</p>	<p>n. Equity increased by ₱118.44M primarily due to the additional share premium and issuance of share capital for the year. This was negated by the negative result of operation from December 2023.</p>

Material Changes in Operating Results

2025 vs. 2024	2024 vs. 2023	2023 vs. 2022
<p>a. Revenue increased by 94.46% The Hospital is in its second year of full operation and gained more patients as compared to 2024 which is just the start of full operation.</p>	<p>a. Revenue increased by 24,781% This was due to start of the Company's full operation of the hospital 2024.</p>	<p>a. Revenue increased by 100% This was due to start of the Company's full operation of the hospital in December 2023.</p>
<p>b. Cost of sales and services increased by 55.66% As the Company gained more patient and started creating a name in Tagum on its second year of full operation, the increase in revenue would also means increase in cost of sales and services</p>	<p>b. Cost of sales and services increased by 5,099% This was directly associated with the start of the Company's full operation in 2024. The major component of the cost of sales and services are employee's compensation and benefits, supplies, depreciation, outside services, utilities, dietary expenses and professional fees.</p>	<p>b. Cost of sales and services increased by 100% This was directly associated with the start of the Company's full operation in December 2023. The major component of the cost of sales and services, employee's compensation and benefits, supplies, depreciation, outside services, utilities, dietary expenses and professional fees.</p>
<p>c. Other income increased by 39% This was mainly due hospital's second year of full operation which have gained additional patients, increasing the income from canteen and other miscellaneous income.</p>	<p>c. Other income increased by 772% This is primarily due to increase in interest income, income from cafeteria and miscellaneous income in relation to the operation of the hospital.</p>	<p>c. Other income increased by 4,232% This is primarily due to increase in interest income, income from cafeteria and miscellaneous income in relation to the operation of the hospital.</p>
<p>e. Operating expenses increased by 57% This is primarily due to additional administrative expenses of the Company such as salaries and wages, taxes and licenses, transportation expenses, communication expenses, professional fee, repairs and maintenance and bank charges.</p>	<p>e. Operating expenses increased by 47% This is primarily due to increase in taxes and licenses, transportation, professional fee, salaries and wages insurance, recruitment expenses, outside services, office supplies and all expenses in relation to the full operation of the hospital.</p>	<p>e. Operating expenses increased by 971% This is primarily due to increase in taxes and licenses, professional fee, salaries and wages insurance, recruitment expenses, outside services, office supplies and all expenses in relation to the full operation of the hospital in</p>

		December 2023.
f. Finance costs increased by 1.62% This was due to deferment of payment of principal.	f. Finance costs increased by 1,636% This was due to deferment of payment of principal and because some of the interest in prior years are capitalized as part of the qualifying asset.	f. Finance costs increased by 100% Because the interest in prior years are capitalized as part of the qualifying asset.
g. Income tax benefit decreased by 146.59% resulting to income tax expense This is due to the positive result of operation for the year 2025.	f. Income tax benefit increased by 43% due to higher expenses resulting to higher taxable loss for the year 2024.	f. Income tax benefit increased by 1,247% due to higher expenses resulting to higher taxable loss for the year 2023.
g. Loss for the year decreased by 131.31% resulting to a net income for the year 2025 The positive result of operation in 2025 as compared to loss in 2024 is attributable to the Company's effort to make TGMCI known in Tagum area, gaining more patients on its second year of operation.	g. Loss for the year increased by 79% primarily due to the significant increase of expenses as the Company started the full operation of the hospital 2024.	g. Loss for the year increased by 1,155% Primarily due to the significant increase of expenses as the Company started the full operation of the hospital in December 2023.

There are no known trends, events or uncertainties that have material impact on liquidity. Nevertheless, Management still continues to pursue intensive efforts to improve cash management.

There are no events that will trigger direct or contingent financial obligation that is material to the Company.

There are no material off-balance sheet transactions, arrangements, obligations and other relationships of the Company with unconsolidated entities or other persons created during the reporting period.

The Company continues to spend for capital expenditures in relation to the construction of the hospital building and acquisition of hospital equipment, office equipment /furniture and fixtures and transportation equipment. These are funded by the proceeds from the offer and bank loans.

The Company start the full operation of the hospital in December 2023.

The financial condition or results of operations of the Company are not affected by any seasonal change.

The Company is not involved in legal proceedings, tax and/or regulatory assessments.

Financial Risks

1. Interest Rate Risk – The Company's interest rate risk is limited to its cash in banks and loans payable.

2. Credit Risk – The Company's credit risk is primarily attributable to its cash and receivables. The Company has adopted stringent procedure in extending credit terms and in monitoring its credit risk. The TGMCI -SEC 17A-v.1 final

Company limits its exposure to credit risks by depositing its cash only with financial institutions duly evaluated and approved by the BOD. The Company's exposure on receivables is minimal since the Company is still at pre-operating stage.

3. Liquidity Risk – As part of the Company's overall liquidity management, the Company maintains a level of cash deemed sufficient to finance operations and to mitigate the effects of fluctuation in cash flows and a balance between continuity of funding and flexibility through the use of bank loans and advances from related parties, if there's any.

The Company has no investments in foreign securities.

Material changes on line items in the financial statements are included in "Management's Discussion and Analysis" above (refer to pages 10-22).

B. Information on Independent Accountant and Other Related Matters

The Company's external auditor is the auditing firm of Perez, Sese, Villa & Co., CPA'S. The same auditing firm is being recommended by the Board, based on the recommendation of the Audit Committee composed of Dr.Lou Josephine Apolinario (Chairman), Dr.Aryeel C. Llanos (Independent) and Dr.Orlando A. Valencia (Independent), for re-appointment as the Company's external auditor for the fiscal year 2025, for a fee of Php250,000.00 (inclusive of VAT).

- a. The Audit committee evaluates proposals based on the quality of service, commitment for deadline and fees. The committee may require a presentation from each proponent to clarify some issues.
- b. Perez, Sese, Villa & Co., CPA'S, represented by its engagement partner, Ms. Alma Sese is the external auditor of the Company for the most recently completed year 2025. Pursuant to SRC Rule 68 (3) (b) (iv) of the Amended Implementing Rules and Regulations of the Securities Regulation Code (SRC) (re: rotation of external auditors), the Company has not engaged Ms. Alma Sese for more than five years.
- c. Representatives of Perez, Sese, Villa & Co., CPA'S. are expected to be present during the stockholders' meeting. The representatives will have the opportunity to make statements if they desire to do so and will be available to respond to appropriate questions from the security holders.
- d. During the two (2) most recent fiscal years or any subsequent interim period, the independent auditor has not resigned nor was dismissed or has declined to stand for reappointment after the completion of the current audit.
- e. The aggregate annual external audit fees billed for each of the last two (2) fiscal years for the audit of the registrant's annual financial statements or services that are normally provided by the external auditor are as follows:

For the year 2025	- P 317,500.00 (billed and paid in 2025)
For the year 2024	- P 390,589.30 (billed and paid in 2024)
- f. The above audit fees are inclusive of the following: (a) audit, other assurance and related services by the External Auditor that are reasonably related to the performance of the audit or review of the Company's financial statements.

The Audit Committee has the function of assessing the independence and professional qualifications of the external auditor, in compliance with the requirements under applicable law, rules and regulations; reviewing the performance of the external auditors; and recommending to the Board of Directors the appointment or discharge of external auditors as well as reviewing and approving audit related and non-audit services to be rendered by external auditors. Prior to the commencement of the audit, the Audit Committee shall discuss, review and recommend with the external auditors the nature, scope and fees of the audit, and ensure proper coordination, if more than one audit firm is involved in the activity to secure proper coverage and minimize duplication of efforts.

PART IV – MANAGEMENT AND CERTAIN SECURITY HOLDERS

(A) Directors, Executive Officers

(1) Directors

There are fifteen (15) members of the Board, two (2) of whom are independent directors. The term of office of each member is one (1) year; they are elected at the annual stockholders' meeting to hold office until the next succeeding annual stockholders' meeting and until his/her successor is elected and qualified. A director who is elected to fill any vacancy holds office only for the unexpired term of his predecessor. The following are the current members of the Board of Directors:

	Name	Business and/or Professional Work Experience
1.	Enriquez, Amado Manuel Jr. C. 73 years old, Filipino	Chairman of the Board: <ul style="list-style-type: none"> - ACE Medical Center Baliwag (2015-Present) - ACE Medical Center Pateros (2013-Present) - ACE Malolos Center Doctors (2015-Present) - ACE Medical Center Mandaluyong (2016-Present) - ACE Medical Center Palawan (2017-Present) - ACE Medical Center Tacloban (2014-Present) - ACE Medical Center Bohol (2014-Present) - ACE Medical Center Dumaguete (2014-Present) - ACE Medical Center General Santos (2016-Present) - ACE Medical Center CDO (2016-Present) - ACE Medical Center Butuan (2016-Present) - ACE Medical Center Bayawan (2015-Present) - ACE Medical Center Legazpi (2016-Present) - ACE Medical Center Dipolog (2017-Present) - ACE Medical Center Quezon City (2012-Present) - ACE Medical Center Tuguegarao (2016-Present) - Tagum Global Medical Center, Inc. (2018-Present)
2.	Enriquez, Michael Edward R. 34 years old, Filipino	Post Graduate Studies: 2017-Doctor of Medicine, University of Santo Tomas Faculty of Medicine and Surgery. 2016-Master in Hospital Management, St. Joseph College. College Degree: 2009-BA Economics, University of Maryland, Baltimore. Secondary Education 2005-Xavier School. Medical Internship/Post - Graduate Training/Residency Training: Post Graduate Internship-UP Philippine General Hospital. Professional Examination Passed -2018. Work Experience and Clinical History /Positions Held: Unihealth-Paranaque Hospital and Medical Center, Sucat - President -CEO ACE Medical Center Baypointe -Treasurer ACE Medical Center Valenzuela-CFO

		<p>ACE Medical Center Baliwag-Finance Head ACE Medical Center Pateros -Treasurer ACE Medical Center Quezon City-Treasurer ACE Medical Center Malolos-Vice President San Jose del Monte Muzon Medical Center-Treasurer ACE Medical Center Cebu -Vice President ACE Medical Center Mandaluyong-Director ACE Medical Center Legazpi-Director ACE Medical Center Palawan-Director ACE Medical Center Tacloban -Director ACE Medical Center Bohol -Director ACE Medical Center Dumaguete-Director ACE Medical Center Bayawan -Director ACE Medical Center Dipolog-Director ACE Medical Center Cagayan de Oro -Director ACE Medical Center General Santos City-Director ACE Medical Center Butuan-Director Tagum Global Medical Center -Director ACE Medical Center Pangasinan-Director ACE Medical Center Sariaya-Director ACE Medical Center Sta.Maria -Director ACE Medical Center Mt.Samat ,Bataan-Director ACE Medical Center La Trinidad ,Baguio-Director ACE Medical Center Hundred Islands -Treasurer ACE Medical Center Santiago-Director ACE Medical Center Balagtas -Director ACE Medical Center La Union-Director ACE Medical Center San Miguel -Director ACE Medical Center Tuguegarao -Director</p>
3.	Miguel Antonio Enriquez,R. 37 years old,Filipino	<p>Visual Arts-Photography 2011-University of Maryland Baltimore Country -USA.Doctor of Dental Medicine -2015 -Centro Escolar University -Manila.Master in Business Administration -2019.University of Makati.Aesthetic Dentistry -one year program -2023.New York University -USA.Rosero Dentistry -Dentist 2016-2026.Kenotes Dental Review Center -Co-Founder (2016-2020). No Edit Dental Photography -2024-2026-Educator & Lecturer.</p>
4.	The estate of Enriquez, Marilyn R. 78 years old, Filipino	<p>Bachelor of Science in Dentistry: University of the East Ramon Magsaysay graduated 1970.Founder ,Rosero Dentistry ,Quezon Philippines.Medical Internship /Post Graduate Training /Residency Training : Master in Healthcare Administration-St.Jude College. Director: ACE Medical Center Tacloban-2023-present ACE Medical Center Baypointe- present ACE Medical Center Quezon City- present ACE Medical Center Valenzuela ACE Medical Center Baliwag ACE Medical Center Pateros,Metro Manila ACE Medical Center Malolos ACE Medical Center</p>

		<p>Mandaluyong ACE Medical Center Legazpi ACE Medical Center Palawan ACE Medical Center Cebu ACE Medical Center Tacloban ACE Medical Center Bohol ACE Medical Center Dumaguete ACE Medical Center Bayawan</p>
5.	Esparagoza, Calixto S. 53 years old, Filipino	<p>Elementary -Immaculate Concepcion College, Secondary -Davao City High School.College-Ateneo de Davao University.Graduate Studies : Davao Medical School Foundation-Doctor of Medicine.Graduate Studies- Mandaue City College : Masters in Hospital Administration.Medical Specialist II-Department of Internal Medicine.</p>
6.	Apolinario, Lou Josephine 57 years old, Filipino	<p>Residency Training in Pediatrics: San Pedro, Hospital, Davao City (1998-2001).Doctor of Medicine : Mindanao State University ,Iligan City (1990-1994).Bachelor of Science in Zoology - Mindanao State University (1985-1989).Hospital Affiliations : Medical Mission Group Hospital -Visiting Consultant (2001- present).Tagum Doctors Hospital -Visiting Consultant (2001- present). Tagum Medical City -Visiting Consultant (2023- present).Christ the King Specialist Hospital -Visiting Consultant (2024-present).Tagum^mGlobal Medical Center Inc.-Human Resource Director (present).</p>
7.	Carlos, Julieta B. 61 years old, Filipino	<p>College Course : BS Pharmacy -Centro Escolar University.Medical School : Manila Central University (1989).Post-Graduate Internship : De Los Medical Center- (1990).Residency Training: Ospital ng Makati (1999).Masters in Hospital Administration : St.Joseph's College.</p> <p>Allied Care Experts (ACE) Medical Center Peteros -Purchasing Department Head (2016-present).Allied Care Experts (ACE) Medical Center Quezon City-Purchasing Department (2017- present).Allied Care Experts (ACE) Medical Center Mandaluyong-Corporate Treasurer (2019-present).</p>
8.	Dalisay, Mae T. 59 years old, Filipino	<p>Graduated in Medicine at SWU-MHAM College of Medicine, Cebu City 1989; Finished Residency Training in Pediatrics, Davao Regional Hospital, 2000; Proprietor & General Pediatric Practitioner: Teano- Dalisay Pediatric Clinic, Tagum Doctors Hospital, Inc., Tagum City; President, Phil. Medical Association Davao Del Norte Chapter 2007-2009; Medical Director- Arriegasado General Hospital, Tagum City Davao del Norte 1991- 1992; Medical Coordinator Rotary Club of Tagum North 2009- present; Rotary Club of Tagum North District 3860 President- 2020-2021; Vice President- Tagum Global Medical Center. Inc. 2018 up to present; Hospital Affiliation: Tagum Doctors' Hospital,</p>

		Inc.
9.	Juarez, Mariebeth P. 59 years old, Filipino	Obstetrician and Gynecologist - Fellow in High-Risk Pregnancy and OB-Gyne Ultrasound, Graduated from Manila Central University Felimon D. Tanchoco Medical Hospital 2004, Finished OB-Gyne Residency at Bicol Medical Center, Naga City (1999) Graduate of Davao Medical School Foundation, year 1989; Medical Specialist 3, Obstetrics and Gynecology Department, Davao Regional Medical Center from 2016 to present. Other Hospitals Affiliations; Medical Mission Hospitals, Bishop Regan Memorial Hospital, Tagum Doctors Hospital; Corporate Secretary, Tagum Global Medical Center, Inc. 2018 - to present; Philippine Society of Nephrology Mindanao Chapter 2002-2012; Board of Director Tagum Global Center Inc. 2018-up to present, Other Hospital affiliations: Medical Mission Hospital, Bishop Regan Memorial Hospital, Tagum Doctors hospital; Corporate Secretary -Tagum Global Medical Center, Inc. 2018 to present
10.	Llanos, Aryeel D. 56 years old, Filipino	Graduated in the College of Medicine from Davao Medical School Foundation-1994 Internal Medicine Residency Training at Davao Regional Medical Center 1997-1999 Cardio Fellowship at Philippine Heart Center 2001-2023 Training Officer, Department of Internal Medicine, Davao Regional Medical Center 2006-2009 Chairman, Department of Internal Medicine 2014-2024 Member, Training Corps, Davao Regional Medical Center
11.	Mendoza, Maria Bernarda DJ 57 years old, Filipino	Medical Specialist 2 - Department of OBGYN DRMC 2013 up to Present; Visiting Consultant OB-GYN Department DRMC- 1999 up to 2013; OB-GYN Ultrasound DRMC 1999 — present; In clinical practice since 1999 up to present; Clinica Mendoza consultant 2000 up to present; Board of Directors Tagum Metro Health Service 2007 up to present; Board Treasurer - Tagum Metro Health Services 2018 up to present; Board of Director-Tagum Global Medical Center, Inc. 2018 up to present
12.	Perdido, Evelyn Ross H. 62 years old, Filipino	Proprietor & Obstetrics and Gynecology Practitioner, Perdido Obstetrics and Gynecology Clinic, Tagum Doctors Hospital, Tagum City, Davao del Norte; Graduated from Davao Medical School Foundation (1989); Finished Obstetrics and Gynecology Specialty Training at Davao Regional Medical Center (1998); Corporate Treasurer, ACE-Tagum Global Medical Center, 2018 up to present.
13.	Pono, Glenn A. Years old, Filipino	Graduate studies -University of the Philippines -Master of Science in Clinical Epidemiology. University of Southern Philippines -Mintal-Doctor of Philosophy in Development Research Administration. Davao Regional Medical Center - Medical Specialist IV. Tagum Global Medical Center, Inc. - Medical Director and founder.
14.	Viernes, La Rhaine G. 57 years old, Filipino	Tagum Global Medical Center, Inc.-President (2018-Present); Board of Directors-ACE Palawan (2017-Present); Founder Director-ACE Legazpi (2016-Present); ACE Council President

		<p>(2021-Present); Chairman of the Department of Pediatrics, ACE Tacloban (2019-Present; ACE Medical Centre Tacloban - Board Secretary (2015-2020); ACE Medical Centre Palawan, Board of Director (2017-Present); Council Secretary (2017-2019); MMH Hospital Tacloban City-Active Consultant (2014-Present); Department of Pediatrics, Divine Word Hospital, Consultant Staff (2001-Present); Philippine Pediatric Society- Eastern Visayas-Chapter President (2016-2018); Advisory Board-Philippine Pediatric Society, Eastern Visayas (2019-Present)</p> <p>Hospital Affiliations:</p> <p>ACEMC-Tacloban - Active Consultant (2019-Present); Mother of Mercy Hospital-Active consultant (2014-Present); RTR Hospital - Active Consultant (1998-Present); Divine Word Hospital - Visiting Consultant (1998-Present)</p>
15.	Valencia, Orlando A. 55 years, old Filipino	<p>Anesthesiologist, Graduated from Iloilo Doctors College of Medicine 2000; Residency Training at Davao Regional Hospital; Masteral: Saint Joseph College of Quezon City (Undergrad); Hospital Affiliations: Tagum Doctors Hospital, Aquino Medical Specialist Hospital, Davao Del Norte District Hospital.</p>

(2) Executive Officers

The Company's key executive officers as of 31 December 2025 are as follows:

La Rhaine G. Viernes	- President
Mae T. Dalisay	- Vice-President
Evelyn Ross H. Perdido	- Treasurer
Nimfa L. Nuevas	- Asst. Treasurer
Mariebeth P. Juarez	- Corporate Secretary
Marietta T. Samoy	- Asst. Corporate Secretary

The Officers (per the Company's By-Laws) are elected/appointed annually by the Board of Directors during its organizational meeting, each to hold office for one (1) year until the next organizational meeting of the Board in the following year or until a successor shall have been elected/appointed and shall have qualified.

Incumbent Officers

1. Amado Manuel C. Enriquez	- Chairman, see forgoing Director's Profile
2. Maria Bernarda D.J. Mendoza	- Vice-Chairman, see forgoing Director's Profile
3. La Rhaine G. Viernes	- President, see forgoing Director's Profile
4. Mae T. Dalisay	- Vice-President, see forgoing Director's Profile
5. Evelyn Ross H. Perdido	- Treasurer, see forgoing Director's Profile
6. Nuevas, Nimfa L.	- Asst. Treasurer, see forgoing Director's Profile
7. Mariebeth P. Juarez	- Corporate Secretary, see forgoing Director's Profile
8. Marietta T. Samoy	- Asst. Corporate Secretary, see forgoing Director's Profile

(3) Significant Employees

The Company relies significantly on the continued collective efforts of its senior executive officers and expects each employee to do his share in achieving the Company's goals.

(4) Family Relationships

Except for Chairman, Dr. Amado Manuel C. Enriquez, Jr. who is the husband of Dr. Marilyn Enriquez, the father of Dr. Michael Edward Enriquez and Dr. Miguel Antonio Enriquez, the first cousin of Dr. Fernando P. Carlos; Dr. La Rhaine Viernes who is the wife of Dr. Earl Courtney A. Viernes; Dr. Fernando P. Carlos who is the husband of Dr. Julieta Carlos and the first cousin of Dr. Amado Manuel Enriquez; Dr. Franklin B. Guillano who is the husband of Dr. Victoria P. Guillano; Dr. Maria Bernada Mendoza who is the mother of Dr. James Ryan DJ Mendoza; Engr. Generoso Orillaza is the husband of Dr. Marissa Orillaza, there are no other family relationships up to the fourth civil degree either by consanguinity or affinity among directors, executive officers, persons nominated or chosen by the Company to become directors, or executive officers, any security holder of certain record, beneficial owner or management.

(5) Certain Relationships and Related Transactions

During the last two (2) years, no director of the Company has received or become entitled to receive any benefit by reason of any contract with the Company, a related corporation, a firm of which the director is a member or a company of which a director has a substantial financial interest.

The Company, in the normal course of business, has entered into transactions with related parties principally consisting of:

A summary of the transactions and account balances with related parties are as follows:

December 31, 2025 (Audited)

<u>Nature of Relationship</u>	<u>Nature of Transaction</u>	<u>Amount (current transaction)</u>	<u>Outstanding balance</u>	<u>Terms</u>	<u>Conditions</u>
	Advances from Payments	₱ (26,321,444)	₱ 10,261,874	Non-interest bearing; payable in cash; no scheduled repayment terms	Unsecured
Shareholders	Loans			Interest bearing; payable in cash; no scheduled repayment terms	Unsecured
	Additional loan	5,199,759			
	Payments	-	20,849,759		
	Interest expense	1,929,452		Payable in cash and on demand	Unsecured

December 31, 2024 (Audited)

<u>Nature of Relationship</u>	<u>Nature of Transaction</u>	<u>Amount (current transaction)</u>	<u>Outstanding balance</u>	<u>Terms</u>	<u>Conditions</u>
-------------------------------	------------------------------	-------------------------------------	----------------------------	--------------	-------------------

	Advances from			Non-interest bearing; payable in cash; no scheduled repayment terms	Unsecured
	Advances	₱36,583,318	36,583,318		
Shareholders	Loans	₱29,650,000		Interest bearing; payable in cash; no scheduled repayment terms	Unsecured
	Additional loan Payments	(76,000,000)	15,650,000		
	Interest expense Payments	₱8,632,890 (10,434,479)	-	Payable in cash and on demand	Unsecured

December 31, 2023 (Audited)

Nature of Relationship	Nature of Transaction	Amount (current transaction)	Outstanding balance	Terms	Conditions
	Advances from			Non-interest bearing; payable in cash; no scheduled repayment terms	Unsecured
	Payment	₱(68,332,876)	₱ -		
Shareholders	Loans			Interest bearing; payable in cash; no scheduled repayment terms	Unsecured
	Additional loan Payments	₱ 34,200,000 (2,500,000)	₱ 62,000,000		
	Interest expense Payments	₱5,036,390 (3,234,801)	₱1,801,589	Payable in cash and on demand	Unsecured

Development Bank of the Philippines

The Company entered into two (2) Term Loan Agreement with the Development Bank of the Philippines (DBP) with a total amount of ₱650M. The amount of loan released as at December 2025, 2024 and 2023 amount to ₱650M.

First Term Loan

The first term loan amounting to ₱500M is payable in twelve (12) years inclusive of a three (3) – year grace period on the principal repayment. The principal is payable in thirty-six (36) quarterly amortizations commencing at the end of the thirteenth (13th) quarter from the date of initial loan release until fully paid. The interest is based on DBP's prevailing rates on the date of loan release 5% - 6% per annum with quarterly repricing and is payable quarterly commencing at the end of the 1st quarter after initial loan release.

Under the terms of the agreement, the proceeds of the loan will be used by the Company to partially finance the construction of a seven (7) storey, 2 Level hospital building and roof deck which is located along National Highway, Barangay Visayan Village, Tagum City, Davao Del Norte. The loan was collateralized by a Real Estate Mortgage (REM) with TCT No. 142-2018008220 registered under the name of Tagum Global Medical Center, Inc. with a carrying amount of ₱947,522,065, ₱943,666,232 and ₱955,267,686 as at December 31, 2025, 2024 and 2023, respectively. (Note 11)

The loan agreement with the banks provides certain restrictions and requirements with respect to among others; a) maintenance of debt to equity ratio of 75:25 and 64:36 debt/equity participation mix for the project, b) not to permit the current ratio to be less than 1:1 at any time, c) not to permit the ratio of its net operating income to total debt service to be less than 1.2:1 at any time, d) incurrence of additional long-term indebtedness or guarantees and e) creation of property encumbrances. The Bank grants a one-year relief from compliance with the financial ratios. Accordingly, the provision in the loan agreement will only be imposed in the year following the Company's commencement of its commercial operations.

Second Term Loan

The second term loan amounting to ₱150M is payable in seven (7) years inclusive of a one (1) – year grace period on the principal repayment. The principal is payable in twenty-four (24) quarterly amortizations commencing at the end of the fifth (5th) quarter from the date of initial loan release until fully paid. The interest is based on DBP's prevailing rates on the date of loan release with quarterly repricing and is payable quarterly commencing at the end of the 1st quarter after initial loan release.

Under the terms of the agreement, the proceeds of the loan will be used by the Company to partially finance the acquisition of various hospital machinery and equipment. The loan was collateralized by a Chattel Mortgage (CHM). The carrying value of hospital equipment used as collateral for this loan amounted to ₱85,226,400, ₱80,622,012, and ₱69,359,207 as at December 31, 2025, 2024, and 2023, respectively. (Note 11)

The loan agreement with the banks provides certain restrictions and requirements with respect to among others; a) maintenance of debt to equity ratio of 75:25 and 64:36 debt/equity participation mix for the project, b) not to permit the current ratio to be less than 1:1 at any time, c) not to permit the ratio of its net operating income to total debt service to be less than 1.2:1 at any time, d) incurrence of additional long-term indebtedness or guarantees and e) creation of property encumbrances. The Bank grants a one-year relief from compliance with the financial ratios. Accordingly, the provision in the loan agreement will only be imposed in the year following the Company's commencement of its commercial operations.

In third quarter of 2023, DBP approved the Company's request for the deferment of the principal repayment of Term Loan 1. The principal repayment which was due in 2023 were added to 2024 quarterly repayment. Consequently, DBP returned the first principal repayment paid by the Company last December 2023.

(6) Involvement in Certain Legal Proceedings

The following are parties to legal proceedings in their capacity as directors/ officers of Allied Care Experts (ACE) Medical Center-Cebu, Inc., as they were the incumbent directors when the cases were filed in 2018:

1. Geanie Cerna-Lopez
2. Amado Manuel C. Enriquez, Jr.
3. Marietta T. Samoy

1. Civil Case No. R-CEB-18-01248-CV, Branch XI, Cebu City (Complaint for Declaration of Sale in Installment as Subscription Contract, Declaration of Rights or Pre-Emption, and for Attorney's Fees) - Dax Matthew M. Quijano, Rosemarie P. Quijano, Eric Y. Cheung, Girlie Cheung, Candice Joy A. Sia vs. ACE Medical Center-Cebu, Inc., Geanie Cerna-Lopez, Velma T. Chan, Luisito R. Co, Maita Cruz, Roberto M. De Leon, Amado Manuel C. Enriquez Jr., Floram C. Limotlimot, Roland Mark M.

Gigataras, Joy C. Luna, Nicolas S. Molon, Felix P. Nolasco, Generoso M. Orillaza, Ronald L. Ramiro, Marietta T. Samoy and Evangeline Y. Zozobrado

On March 7, 2018, complainants Dax Matthew M. Quijano, Rosemarie P. Quijano, Eric Y. Cheung, Girlie Cheung, Candice Joy A. Sia, through counsel filed a civil complaint against the Hospital and its Directors (as stated above) praying the Court to direct the defendants ACE Medical Center Cebu and its President and Corporate Secretary to issue the plaintiff's Certificate of Stock and declare the sale in installment as subscription contract, to allow him to exercise pre-emptive rights to the increase in capital approved by the Board on November 12, 2016.

The Defendants have already filed their Answer to the Complaint.

Complainant filed a Motion to Dismiss the Complaint for lack of interest of the plaintiffs to prosecute the case last August 5, 2020. A Judicial Dispute Resolution was scheduled but failed. Case is up for pre-trial conference.

The judicial dispute resolution (JDR) failed. The case was up for pre-trial conference on 20 October 2023 at 10:00 in the morning, after several postponements. During the 20 October 2023, the plaintiffs' counsel asked the Court to render a partial judgment recognizing the sale in installment as a subscription contract. We objected and requested that their request for partial judgment be put into writing so that we can make an informed comment on the matter. Plaintiffs were given 15 days to file and the same number of days was granted to us to comment on their filing. The next pre-trial is scheduled on 22 December 2023 at 10:00 in the morning. The 22 December 2023 hearing was reset to 15 March 2024 at 10:30 am. The 15 March 2024 hearing was moved to 22 April 2024 at 9:15 am since the Court needs time to evaluate the motion for partial summary judgment.

2. Civil Case No. R-CEB-18-00601-CV, Branch XI, Cebu City (Complaint for Issuance of Certificate of Stock, Declaration of Sale in Installment as Subscription Contract, Declaration of Rights or Pre-Emption, and for Attorney's Fees) – Ferdinand P. Kionisala vs. Allied Care Experts (ACE) Medical Center-Cebu, Inc., Geanie Cerna-Lopez, Velma T. Chan, Luisito R. Co, Maita Cruz, Roberto M. De Leon, Amado Manuel C. Enriquez, Jr., Floram C. Limotlimot, Roland Mark M. Gigataras, Joy C. Luna, Nicolas S. Molon, Felix P. Nolasco, Generoso M. Orillaza, Ronald S. Ramiro, Marietta T. Samoy, and Evangeline Y. Zozobrado

On February 5, 2018, complainant Ferdinand P. Kionisala filed a civil complaint against the Hospital and its Directors (as stated above) praying the Court to direct the defendants ACE Medical Center Cebu and its President and Corporate Secretary to issue the plaintiff's Certificate of Stock and declare the sale in installment as subscription contract, to allow him to exercise pre-emptive rights to the increase in capital approved by the Board on November 12, 2016.

The Defendants (based in Cebu) have already filed their Answer to the Complaint and Dr. Kionisala has filed a Motion for Partial Summary Judgment, but the same was opposed by the defendants on May 15, 2018. The Court has not yet ruled on the plaintiff's Motion for Partial Summary Judgment of May 2, 2018. Unless the Court resolves the Motion for Summary Judgment by the plaintiff, the case will not move on.

The Defendants filed a Motion to Dismiss the case for failure of the plaintiff to prosecute for lack of interest. The case was scheduled for Pre-Trial on April 30, 2021. Pre-trial was terminated. Case is set for presentation of plaintiff's evidence.

The Court rendered on August 9, 2022 a partial summary judgement on plaintiff's prayer for issuance of certificate of stock leaving the other issues sought for trial on the merits.

Plaintiff has submitted his motion to submit case for decision based on legal issues, which was submitted to the Court on October 24, 2022. We filed our comment on November 7, 2022. We received an order dated 30 June 2023 where the Court has granted the motion to submit case for decision based on legal issues dated 18 October 2022. The Presiding Judge has granted both parties to file their respective memorandum, which shall be limited to the issue of the extent of plaintiff's preemptive right to purchase/subscribe to shares of stock in view of the defendant Corporation's increase in its capital stock, within 30 days from receipt of said order. Our Counsel filed a Motion for Reconsideration to set aside and deny Plaintiff's motion to submit case for decision based on the sole issue of whether the plaintiff is entitled to the preemptive right to subscribe to one block of share equivalent to 10 shares or only for 3 shares for utter lack of merit. The Plaintiff's Counsel opposed the Motion for Reconsideration filed by our Counsel. Awaiting decision of the Court on both Motions.

3. Special Civil Action Case No. R-CEB-18-08795-SC, Branch XI, Cebu City (For Mandamus to Issue 100% Pre-Emptive Rights, Damages and for Attorney's Fees) - Leo T. Sumatra, Sps. Stephen Paul M. Bergado and Conchita B. Bergado, Marie Davielene Beatriz Ong-Dy and Leonard Matthew Dy, et. Al vs. Allied Care Experts (ACE) Medical Center-Cebu, Inc., Geanie Cerna-Lopez and Velma T. Chan

The Petitioners have filed a Special Civil Action case for Mandamus, to compel the Respondents to immediately issue their 100% pre-emptive rights. The Petitioners claim they are entitled to 10 shares based on their computation of 0.000083333 ownership multiplied by 120,000 (increase in Capital).

Respondents received the Court Order on 11 December 2018. On November 25, 2020 at 8:30AM, a Judicial Dispute Resolution was conducted by RTC Branch 12, Cebu City via video conference hearing. Both parties did not come into an agreement. The Petitioners demanded PHP 600,000.00 from the Respondents. The case was scheduled for Pre-Trial on June 11, 2021. Pre-trial was terminated. Case is set for presentation of petitioners' evidence.

Presentation of petitioners' evidence. Petitioners have so far presented two (2) witnesses.

Petitioners have submitted their motion to submit case for decision based on legal issues, which was submitted on November 7, 2022. Case has been submitted for resolution. Last February 3, 2023, the scheduled hearing pushed through, and Counsel appeared for and on behalf of ACEMCCEBU, despite the pending motion. On February 15, 2023, the Court denied the request of the Petitioners' motion to submit the case for decision based on the remaining sole legal issue. As stated in the Order, the presentation of evidence for the petitioners will push through as scheduled on 03 March 2023 at 10:45 in the morning. The hearing was cancelled upon receipt of a Constancia dated 27 February 2023 and reset to 28 April 2023 at 10:45 in the morning. During the 28 April 2023 hearing, the Court still needs to resolve the pending Motion for Reconsideration filed by the Petitioners. Without prejudice to the resolution of the pending incident, the next hearing is set at on 30 June 2023 at 10:45am for presentation of Petitioners' evidence. Considering petitioners' motion for reconsideration has yet to be resolved, the 30 June 2023 hearing was reset to 28 July 2023 at 10:45 am. Due to the pending motion for reconsideration, the 28 July 2023 hearing was reset to 25 August 2023 at 10:45am. The 25 August 2023 was rescheduled to 29 September 2023 at 10:45am. The 29 September 2023 hearing was reset to 14 December 2023 at 10:45am. The 14 December 2023 hearing was reset to 15 March 2024 at 8:30am. The 15 March 2024 was moved to 19 April 2024 at 8:30AM since the witness of the petitioner's did not show up.

No director has resigned or declined to stand for re-election to the board of directors since the date of the last annual meeting of security holders due to disagreement with the registrant on any matter relating to the registrant's operations, policies and practices.

(B) Compensation of Directors and Executive Officers

SUMMARY COMPENSATION TABLE

(a) Name & Principal Position	(b) Year	(c) Salary	(d) Bonus	(e) Other Compensation
A. Amado Manuel C. Enriquez Jr. Chairman	2025	-0-	- 0 -	- 0 -
B. La Rhaine G. Viernes President	2025	-0-	- 0 -	- 0 -
C. Evelyn Ross H. Perdido Corporate Treasurer	2025	-0-	- 0 -	- 0 -
D. Mariebeth Juarez Corporate Secretary	2025	-0-	- 0 -	- 0 -
E. Aggregate For The Above Named CEO & Officers	2025-estimate	-0-	- 0 -	- 0 -
	2024	-0-	- 0 -	- 0 -
	2023	-0-	- 0 -	- 0 -
F. Aggregate For The Officers And Directors As A Group	2025-estimate	-0-	- 0 -	- 0 -
	2024	-0-	- 0 -	- 0 -
	2023	- 0 -	- 0 -	- 0 -

Except for per diem (P20,000.00/ board meeting) during board meetings for each director, there are no bonus, profit sharing or other compensation plan, contract or arrangement in which any director, nominee for election as director, or executive officers of the registrant will participate.

The Company has no existing options, warrants or rights to purchase any securities.

(C) Security Ownership of Certain Record and Beneficial Owners

(1) The persons known to the registrant to be directly or indirectly the record or beneficial owner of more than 5% of the registrant's voting securities as of 31 December 2025 are as follows:

Title of Class	Name, Address of record owner and Relationship with Issuer	Name of Beneficial Owner and Relationship with Record Owner	Citizenship	Shares Held	Percent
Common	Enriquez, Amado Manuel Jr.	Enriquez, Marilyn R.-wife Enriquez, Michael Edward R.-son Enriquez, Miguel Antonio R.-son	Filipino	30,510 (Direct) 23,730 (Indirect)	26.10%
Common	Enriquez, Michael Edward R.	Enriquez, Amado Manuel Jr.-father Enriquez, Marilyn R.-mother Enriquez, Miguel Antonio R.-brother	Filipino	10,170 (Direct) 44,070 (Indirect)	26.10%
Common	Enriquez, Miguel Antonio R.	Enriquez, Amado Manuel Jr.-father	Filipino	10,170 (Direct) 44,070 (Indirect)	26.10%

		Enriquez, Marilyn R.-mother Enriquez, Michael Edward R.- brother			
Common	Enriquez, Marilyn R.	Enriquez, Amado Manuel Jr.- husband Enriquez, Miguel Antonio R.- son Enriquez, Michael Edward R.- son	Filipino	3,390 (Direct) 50,850 (Indirect)	26.10%

(2) Security Ownership of Directors and Management as of 31 December 2025:

(1) Title of Class	(2) Name of Beneficial Owner	Position	(3) Amount and Nature of Beneficial Ownership	(4) Citizenship	(5) Percentage (%) of Class
Common	Carlos, Fernando P.	Director	3,390 (Direct) 3,390 (Indirect)	Filipino	3.26%
Common	Dalisay, Mae T.	Director/ Vice- President	6,780 (Direct)	Filipino	3.26%
Common	Enriquez, Amado Manuel Jr.	Director/ Chairman	30,510 (Direct) 23,730 (Indirect)	Filipino	26.10%
Common	Enriquez, Michael Edward	Director	10,170 (Direct) 44,070 (Indirect)	Filipino	26.10%
Common	Esparagoza, Calixto S.	Independent Director	3,390 (Direct) 3,390 (Indirect)	Filipino	3.26%
Common	Guillano, Franklin B.	Director/ Asst. Secretary	3,390 (Direct) 3,390 (Indirect)	Filipino	3.26%
Common	Juarez, Mariebeth P.	Director/ Secretary	3,390 (Direct)	Filipino	1.63%
Common	Cerna-Lopez, Geanie	Director	3,390 (Direct)	Filipino	1.63%
Common	Mendoza, Maria Bernarda DJ	Director/ Vice- Chairman	3,390 (Direct) 3,390 (Indirect)	Filipino	3.26%
Common	Nuevas, Nimfa L.	Director/ Asst. Treasurer	3,390 (Direct)	Filipino	1.63%
Common	Perdido, Evelyn Ross H.	Director/ Treasurer	3,390 (Direct)	Filipino	1.63%
Common	Quilisadio, John Elmer C.	Independent Director	3,390 (Direct)	Filipino	1.63%
Common	Samoy, Marietta T.	Director	3,390 (Direct)	Filipino	1.63%
Common	Valencia, Orlando	Independent Director	3,390 (Direct)	Filipino	1.63%
Common	Vienes, La Rhaine G.	Director/ President	3,390 (Direct) 3,390 (Indirect)	Filipino	3.26%
Total for Directors			88,140 (Direct)		42.40%

Executive Officers:

Common	Viernes, La Rhaine G.	President	3,390 (Direct) 3,390 (Indirect)	Filipino	3.26%
Common	Dalisay, Mae T.	Vice - President	6,780 (Direct)	Filipino	3.26%
Common	Perdido, Evelyn Ross H.	Treasurer	3,390 (Direct)	Filipino	1.63%
Common	Nuevas, Nimfa L.	Asst. Treasurer	3,390 (Direct)	Filipino	1.63%
Common	Juarez, Mariebeth P.	Secretary	3,390 (Direct)	Filipino	1.63%
Common	Guillano, Franklin B.	Asst. Secretary	3,390 (Direct) 3,390 (Indirect)	Filipino	3.26%
Total for Officers			23,730 (Direct)		11.42%
Common	Directors and Exec. Officers as a Group		88,140 (Direct)		42.40%

The following directors and management own directly or indirectly 2% or more of the outstanding capital stock of the Company:

Name	Percentage of Ownership		Total
	Direct	Indirect	
Enriquez, Amado Manuel Jr.	14.68%	11.42%	26.10%
Enriquez, Michael Edward R.	4.89%	21.20%	26.10%
Dalisay, Mae T.	3.26%		3.26%
Esparagoza, Calixto S.	1.63%	1.63%	3.26%
Guillano, Franklin B.	1.63%	1.63%	3.26%
Mendoza, Maria Bernarda DJ	1.63%	1.63%	3.26%
Viernes, La Rhaine G.	1.63%	1.63%	3.26%

- (3) There are no voting trust holders of 5% or more.
- (4) The Company is not aware of any voting trust agreement/s or similar agreement/s which may result in a change in control of the Company.
- (5) No change in control of the registrant has occurred since the beginning of its last fiscal year.

(D) Certain Relationships and Related Transactions

The Company's related parties include its affiliates and shareholders, the Company's key management personnel and others as described below.

A summary of the transactions and account balances with related parties are as follows:

December 31, 2025 (Audited)

Nature of Relationship	Nature of Transaction	Amount (current transaction)	Outstanding balance	Terms	Conditions
Shareholders	Advances from Payments	₱ (26,321,444)	₱ 10,261,874	Non-interest bearing; payable in cash; no scheduled repayment terms	Unsecured

Loans				Interest bearing; payable in cash; no scheduled repayment terms	Unsecured
Additional loan	5,199,759				
Payments	-	20,849,759			
Interest expense	1,929,452			Payable in cash and on demand	Unsecured

December 31, 2024 (Audited)

Nature of Relationship	Nature of Transaction	Amount (current transaction)	Outstanding balance	Terms	Conditions
	Advances from			Non-interest bearing; payable in cash; no scheduled repayment terms	
	Advances	₱36,583,318	36,583,318		Unsecured
Shareholders	Loans	₱29,650,000		Interest bearing; payable in cash; no scheduled repayment terms	
	Additional loan				
	Payments	(76,000,000)	15,650,000		Unsecured
	Interest expense	₱8,632,890		Payable in cash and on demand	
	Payments	(10,434,479)	-		Unsecured

December 31, 2023 (Audited)

Nature of Relationship	Nature of Transaction	Amount (current transaction)	Outstanding balance	Terms	Conditions
	Advances from			Non-interest bearing; payable in cash; no scheduled repayment terms	
	Payment	₱(68,332,876)	₱ -		Unsecured
Shareholders	Loans			Interest bearing; payable in cash; no scheduled repayment terms	
	Additional loan	₱ 34,200,000			
	Payments	(2,500,000)	₱ 62,000,000		Unsecured
	Interest expense	₱5,036,390		Payable in cash and on demand	
	Payments	(3,234,801)	₱1,801,589		Unsecured

Development Bank of the Philippines

The Company entered into two (2) Term Loan Agreement with the Development Bank of the Philippines (DBP) with a total amount of ₱650M. The amount of loan released as at December 2025, 2024 and 2023 amount to ₱650M.

First Term Loan

The first term loan amounting to ₱500M is payable in twelve (12) years inclusive of a three (3) – year grace period on the principal repayment. The principal is payable in thirty-six (36) quarterly amortizations commencing at the end of the thirteenth (13th) quarter from the date of initial loan release until fully paid. The interest is based on DBP's prevailing rates on the date of loan release 5% - 6% per annum with quarterly repricing and is payable quarterly commencing at the end of the 1st quarter after initial loan release.

Under the terms of the agreement, the proceeds of the loan will be used by the Company to partially finance the construction of a seven (7) storey, 2 Level hospital building and roof deck which is located along National Highway, Barangay Visayan Village, Tagum City, Davao Del Norte. The loan was collateralized by a Real Estate Mortgage (REM) with TCT No. 142-2018008220 registered under the name of Tagum Global Medical Center, Inc. with a carrying amount of ₱947,522,065, ₱943,666,232 and ₱955,267,686 as at December 31, 2025, 2024 and 2023, respectively. (Note 11)

The loan agreement with the banks provides certain restrictions and requirements with respect to among others; a) maintenance of debt to equity ratio of 75:25 and 64:36 debt/equity participation mix for the project, b) not to permit the current ratio to be less than 1:1 at any time, c) not to permit the ratio of its net operating income to total debt service to be less than 1.2:1 at any time, d) incurrence of additional long-term indebtedness or guarantees and e) creation of property encumbrances. The Bank grants a one-year relief from compliance with the financial ratios. Accordingly, the provision in the loan agreement will only be imposed in the year following the Company's commencement of its commercial operations.

Second Term Loan

The second term loan amounting to ₱150M is payable in seven (7) years inclusive of a one (1) – year grace period on the principal repayment. The principal is payable in twenty-four (24) quarterly amortizations commencing at the end of the fifth (5th) quarter from the date of initial loan release until fully paid. The interest is based on DBP's prevailing rates on the date of loan release with quarterly repricing and is payable quarterly commencing at the end of the 1st quarter after initial loan release.

Under the terms of the agreement, the proceeds of the loan will be used by the Company to partially finance the acquisition of various hospital machinery and equipment. The loan was collateralized by a Chattel Mortgage (CHM). The carrying value of hospital equipment used as collateral for this loan amounted to ₱85,226,400, ₱80,622,012, and ₱69,359,207 as at December 31, 2025, 2024, and 2023, respectively. (Note 11)

The loan agreement with the banks provides certain restrictions and requirements with respect to among others; a) maintenance of debt to equity ratio of 75:25 and 64:36 debt/equity participation mix for the project, b) not to permit the current ratio to be less than 1:1 at any time, c) not to permit the ratio of its net operating income to total debt service to be less than 1.2:1 at any time, d) incurrence of additional long-term indebtedness or guarantees and e) creation of property encumbrances. The Bank grants a one-year relief from compliance with the financial ratios. Accordingly, the provision in the loan agreement will only be imposed in the year following the Company's commencement of its commercial operations.

In third quarter of 2023, DBP approved the Company's request for the deferment of the principal repayment of Term Loan 1. The principal repayment which was due in 2023 were added to 2024 quarterly repayment. Consequently, DBP returned the first principal repayment paid by the Company last December 2023.

PART V – CORPORATE GOVERNANCE

The Company adheres to the principles of good governance as provided in its Manual on Corporate Governance (MCG). The directors, officers and employees perform their duties and responsibilities in accordance with the mission and vision of the Company and the corporate practices pursuant to its Manual on Corporate Governance. The Board committees, including the Nominations and Audit committees, have complied with their duties and responsibilities under the MCG. There were no major deviations from the adopted Manual on Corporate Governance.

The Company, in pursuit of its mission and vision, likewise implemented the following programs/activities:

The directors and officers of the Corporation have attended a Corporate Governance Seminar on January 27, 2023.

The Independent directors have submitted their Certificates of Qualification as required by the SEC vis-à-vis Section 38 of the Securities Regulation Code.

PART VI - EXHIBITS AND SCHEDULES

(a) Exhibit

* 2025 Audited Financial Statements

(b) Reports on SEC Form 17-C

Date	Disclosures
April 21,2025	Appointment of Independent Accountant
June 2,2025	Election of Officers
June 6,2025	Election of Directors
July 1 , 2025	Resignation of Director/ Election of Replacement

SIGNATURES

Pursuant to the requirements of Section 17 of the Securities Regulation Code and Section 141 of the Corporate Code of the Philippines, this amended annual report has been signed on behalf of the issuer, by the following persons in the capacities and on the dates indicated.



LA RHAINÉ G. VIERNES
President



MARIEBETH P. JUAREZ
Corporate Secretary



EVELYN ROSS H. PERDIDO
Tresurer

NOTE: There is no "Comptroller" position in the existing organizational structure of Tagum Global Medical Center Inc.

SUBSCRIBED AND SWORN to before me this 28th day of April 2026, in Tagum City, affiants exhibited to me their Tax Identification Number (TIN), as follows:

AFFIANTS	TIN Nos.
Mariebeth P. Juarez	163-371-436
Evelyn Ross H. Perdido	124-981-284
La Rhaine G. Viernes	186-891-699

